Jagsonpal Pharmaceuticals Ltd vs Pentokey Organy India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 213.35 as of 07 May 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 yearsThe P/E Ratio of Pentokey Organy (India) Ltd changed from 8.2 on March 2023 to 81.2 on March 2025 . This represents a CAGR of 114.74% over 3 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 yearsThe Market Cap of Pentokey Organy (India) Ltd changed from ₹ 6.83 crore on March 2021 to ₹ 19.84 crore on March 2025 . This represents a CAGR of 23.77% over 5 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Dec '25 revenue of ₹ 75.92 crore. This represent the decline of -11.26% The revenue of Pentokey Organy (India) Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ -2.01 crore. This represent the decline of -100% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Dec '25 ebitda of ₹ 17.16 crore. This represent the decline of -16.49% The ebitda of Pentokey Organy (India) Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ -0.29 crore. This represent the decline of -100% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 8.76 crore over 8 quarters. This represents a CAGR of 28.20% The net profit of Pentokey Organy (India) Ltd changed from ₹ 0.05 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 yearsThe Dividend Payout of Pentokey Organy (India) Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Pentokey Organy (India) Ltd

Pentokey Organy (India) Limited was incorporated on November 26, 1986.
The Company is engaged in the trading of Pharmaceutical products such as Acetic Acid, Ethyl Acetate and Acetaldehyde.
Ethyl Acetate is preferred by customers in all markets as it is fast replacing the petroleum-based solvents such as Toluene, MEK (Methyl Ethyl Ketone), MIBK (Methyl Iso Butyl Ketone) etc. In 2012-13, the production of intermediate product namely Acetic Acid was not competitive due to market prices.
Company therefore purchased the Acetic Acid from market instead of producing the same from Ethanol or Acetaldehyde.
As a result of this, production of Acetaldehyde, which is an intermediate product for Acetic Acid, was low.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Pentokey Organy (India) Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Pentokey Organy (India) Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,406 Cr while Market cap of Pentokey Organy (India) Ltd is 25 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Pentokey Organy (India) Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Pentokey Organy (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Pentokey Organy (India) Ltd?

As of May 7, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹209.5. On the other hand, Pentokey Organy (India) Ltd stock price is INR ₹41.07.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Pentokey Organy (India) Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Pentokey Organy (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.